Personalized Lifestyle Intervention and Weight Control

Personalized Lifestyle Intervention Based on SNP Testing and Weight Control

This trial aims to investigate whether tailored lifestyle consultation through SNP testing leads to more effective weight loss among overweight or obese individuals compared to general lifestyle guidance for weight control.

Study Overview

• Status: Completed
• Conditions: Weight Loss
• Intervention / Treatment: Behavioral: Obesity-related genetic information disclosure with tailored lifestyle recommendations; Behavioral: Non-obesity-related genetic information disclosure

• Study Type: Interventional
• Enrollment (Actual): 53
• Phase: Not Applicable

Contacts and Locations

Study Locations

• South Korea
  • Gyeonggi-do
    • Goyang-si, Gyeonggi-do, South Korea, 10326
      • Dongguk University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Korean adults aged 18 years and older who are interested in weight management through dietary and/or exercise therapy.
2. Individuals who are able and willing to participate consistently for the entire 2-year study period.

Exclusion Criteria:

1. Individuals with any illness requiring regular medical treatment in a hospital.
2. Individuals currently taking long-term prescribed medications.
3. Individuals diagnosed with eating disorders or mental illnesses (e.g., depression, panic disorder) by a physician.
4. Individuals who have undergone gastric surgery for weight loss.
5. Individuals who have undergone heart surgery or cancer surgery.
6. Individuals with severe anemia.
7. Individuals who are unable to engage in physical exercise.
8. Pregnant or breastfeeding women, or those planning to become pregnant within 2 years.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Disclosure of obesity-related genetic risk with tailored lifestyle recommendations; Participants received their obesity-related genetic test results, including variants in FTO (rs9939609), MC4R (rs17782313), and BDNF (rs6265), along with genotype-tailored lifestyle recommendations. The counseling materials encouraged risk-allele carriers to adopt healthier behaviors such as reducing fat intake, limiting snacking, and avoiding emotional eating. Personalized genetic results and recommendations were delivered at baseline through a user-friendly report.	Behavioral: Obesity-related genetic information disclosure with tailored lifestyle recommendations; They received their complete SNP results, including obesity-related traits, along with corresponding lifestyle recommendations.
Active Comparator: Disclosure of non-obesity-related genetic traits only; Participants received genetic test results limited to non-obesity-related traits (e.g., beauty-related genes). They did not receive any obesity- or metabolism-related genetic information or tailored lifestyle recommendations. The full obesity-related genetic results were disclosed only after completion of the final follow-up.	Behavioral: Non-obesity-related genetic information disclosure; Provided only with genetic test results related to beauty traits at baseline; information on metabolic health-related SNPs was disclosed only after the final follow-up assessment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Body Weight (kg)	Change was calculated as the value at the later time point minus the value at baseline (i.e., value at about 5 months after randomization minus baseline, and value at study completion (~17 months) minus baseline). Positive values represent increases from baseline, and negative values represent decreases.	About 5 months after randomization and at study completion (~17 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Body Fat Mass (kg)	Change was calculated as the value at the later time point minus the value at baseline (i.e., value at about 5 months after randomization minus baseline, and value at study completion (~17 months) minus baseline). Positive values represent increases from baseline, and negative values represent decreases.	About 5 months after randomization and at study completion (~17 months)
Body Fat Percentage (%)	Change was calculated as the value at the later time point minus the value at baseline (i.e., value at about 5 months after randomization minus baseline, and value at study completion (~17 months) minus baseline). Positive values represent increases from baseline, and negative values represent decreases.	About 5 months after randomization and at study completion (~17 months)
Skeletal Muscle Mass (kg)	Change was calculated as the value at the later time point minus the value at baseline (i.e., value at about 5 months after randomization minus baseline, and value at study completion (~17 months) minus baseline). Positive values represent increases from baseline, and negative values represent decreases.	About 5 months after randomization and at study completion (~17 months)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
body composition (% muscle)	change in body composition from the time of randomization	at six months, 1 year, and 2 years after randomization
body composition (% fat)	change in body composition from the time of randomization	at six months, 1 year, and 2 years after randomization

Collaborators and Investigators

• Sponsor: NaNa Keum
• Collaborators: National Research Foundation of Korea; DongGuk University
• Investigators: Principal Investigator: NaNa Keum, ScD, Dongguk University

Study record dates

Study Major Dates

• Study Start (Actual): June 11, 2019
• Primary Completion (Actual): November 2, 2020
• Study Completion (Actual): November 2, 2020

Study Registration Dates

• First Submitted: February 18, 2019
• First Submitted That Met QC Criteria: September 3, 2019
• First Posted (Actual): September 6, 2019

Study Record Updates

• Last Update Posted (Estimated): January 6, 2026
• Last Update Submitted That Met QC Criteria: December 13, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Body Weight; Body Weight Changes; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Weight Loss
• Other Study ID Numbers: 2018-12-006

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No